Active, not recruiting Rintatolimod/HER2 Pep- tide Vaccine ERB2 HER2+ GM-CSF vs. Ampligen as adjuvant University of Washington Chimeric (trastuzumab- like/pertuzumab-like) HER-2 B-cell peptide vaccine ERB2 HER2+ Ohio State Comprehensive Cancer Center Allogeneic GM-CSF–se- creting breast cancer vaccine/trastuzumab Tumor anti- gens Hormone+_HER2- cyclophosphamide Sidney Kimmel Cancer Center Active, not recruiting Genetically modified lymphocytes NY-ESO-1 All Proleukin, cyclophos- phamide, fludarabine National Cancer Institute HER2 VRP ERB2 HER2+ Duke University Immunomodulators Imiquimod TLR7 (Toll-like receptor 7) All Radiation National Cancer Institute Terminated as of 8/1 Natural killer cells Immunother- apy All Chemotherapy Investigator-initiated NLG919 IDO Pathway All NewLink Genetics Indoximod IDO Pathway Hormone+_HER2- Docetaxel NewLink Genetics Active, not recruiting Agatolimod TLR9 HER2+ Trastuzumab Pfizer  CC-122 Pleiotropic pathway  All Celgene  MK-3475  PD-1 (pro- grammed death 1) TripleNegative Merck PLX3397 CSF-1 receptor (Fms) All Paclitaxel Plexxikon Cyroablation (proce- dure) Immune sys- tem Hormone+_HER2- John Wayne Cancer Institute at Saint John's Health Center Other Heat Shock Protein (Hsp) Ganetespib Hsp90 HER2+ Synta Pharmaceuticals Ganetespib Hsp90 Hormone+_HER2- Fulvestrant Dana-Farber/Harvard Cancer Center Ganetespib Hsp90 All Paclitaxel, traztu- zumab New York University SNX-5422 Hsp90 HER2+ Esanex Incorporated Other Dasatinib BCR-ABL ty- rosine kinase All Paclitaxel Sloan Kettering PF-06647263 Not disclosed All Pfizer  Multiple drugs Mutlple targets All National Cancer Institute Subtotal Targeted Non-Targeted Therapies Cancer Stem Cells BBI608 Cancer stem cells All Paclitaxel Boston Biomedical POL6326 CXCR4 recep- tors Hormone+_HER2- Eribulin Polyphor Chloroquine Cancer stem cells All Paclitaxel, docetaxel, nab-paclitaxel, or ixabepilone Methodist Hospital Houston Vantictumab Cancer stem cells HER2- Paclitaxel  OncoMed Pharmaceuticals Arginine ADI-PEG 20 Arginine HER2- Doxorubicin Polaris Group Chemotherapy Active, not recruiting Pemetrexed All Study Drug(s) Target Biomarkers/ Subtype Combination Sponsor